Factors Associated With Off-Label Utilization of Second-Generation Antipsychotics Among Publicly Insured Adults Article Swipe

View

Related Concepts

Medicaid Medicine Odds ratio Odds Ethnic group Confidence interval Drug Utilization Review Medical prescription Off-label use Antipsychotic Medical Expenditure Panel Survey Environmental health Demography Gerontology Logistic regression Psychiatry Health insurance Schizophrenia (object-oriented programming) Health care Pharmacology Anthropology Sociology Internal medicine Economics Pathology Economic growth

Marcela Horvitz‐Lennon , Rita Volya , Simon Hollands , Katya Zelevinsky , Andrew Mulcahy , Julie M. Donohue , Sharon‐Lise T. Normand ·

YOU? · · 2021 · Open Access · · DOI: https://doi.org/10.1176/appi.ps.202000381 · OA: W3164384335

Off-label utilization of second-generation antipsychotics was prevalent despite the drugs' cardiometabolic risks and little evidence of their effectiveness. The lower likelihood of off-label utilization among patients from racial-ethnic minority groups might stem from prescribers' efforts to minimize risks, given a higher baseline risk for these groups, or from disparities-associated factors. Variation among payers suggests that payer policies can affect off-label utilization.